Physician profile
Melissa Dworkin
NPI 1548307622
$483.50
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $127 · 2021: $15.00.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $83.51 | 2019 | |
| Avion Pharmaceuticals | $73.41 | 2020-2021 | |
| Therapeuticsmd, INC. | $54.67 | 2020 | |
| Lupin INC. | $44.32 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.55 | 2019 | |
| Allergan, INC. | $31.12 | 2019 | |
| Pfizer INC. | $28.12 | 2019 | |
| Coopersurgical, INC. | $28.00 | 2019 | |
| Olympus America INC. | $25.39 | 2019 | |
| Daiichi Sankyo INC. | $23.72 | 2019 | |
| Duchesnay USA Incorporated | $20.99 | 2019 | |
| Vertical Pharmaceuticals, LLC | $19.90 | 2019 | |
| Millicent US INC | $11.80 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Dworkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.